Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of 伯瑞替尼 in c-MET-aberrant advanced non-small cell lung cancer
CTR20191957Phase 2Completed
- Sponsor
- Beijing Purunao Biotechnology
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vebreltinib, sponsored by Beijing Purunao Biotechnology. Started Jan 2020; status: completed.
02
Drugs
vebreltinib
Beyond the preview
Go deeper on CTR20191957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191957.